Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.
[ X ]
Tarih
2025
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
LIPPINCOTT WILLIAMS & WILKINS
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
...
Açıklama
Anahtar Kelimeler
Oncology
Kaynak
Journal of Clinical Oncology
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
43
Sayı
17_SUPPL
Künye
Tolaney, S. M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y. H., Rimawi, M. F., ... & Loibl, S. (2025). Trastuzumab deruxtecan (T-DXd)+ pertuzumab (P) vs taxane+ trastuzumab+ pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. 10.1200/JCO.2025.43.17_suppl.LBA1008
